Abstract
Despite the availability of a wide range of effective blood pressure (BP)-lowering agents, a substantial proportion of patients with hypertension fail to achieve target BP levels. The majority of patients with hypertension need a combination of two or more drugs to achieve BP targets and choice of second-line or subsequent-line therapy is an important consideration in hypertension management. Alpha-1-adrenoreceptor antagonists (alpha-blockers) have a BP-lowering effect broadly similar to the other antihypertensive drug classes and are effective as add-on therapy in patients with inadequately controlled hypertension. Alpha-blockers may also have therapeutic benefits that go beyond BP control, including improvements in lipid profile and glucose metabolism, as well as reducing the symptoms of benign prostatic hyperplasia. Urapidil has an alpha-blocking effect but, unlike other alpha-blockers, also has a central sympatholytic effect mediated via stimulation of serotonin 5HT1A receptors in the central nervous system. Several studies have suggested that oral urapidil is effective and well tolerated when used as second-line therapy in patients with BP inadequately controlled with other agents. Urapidil has also been shown to improve glucose and lipid metabolism in hypertensive patients with concomitant diabetes and/or hyperlipidemia. Intravenous urapidil is effective in the treatment of hypertensive crises, perioperative hypertension, and pre-eclampsia and may have a potential role in the management of acute stroke. In this review, the use of alpha-blockers in hypertension is discussed, with particular focus on urapidil for the lowering of BP in a variety of clinical settings.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Ezzati M, Lopez A, Rodgers A, Vander Hoorn S, Murray CJL, eds. Comparative Quantification of Health Risks: Global and Regional Burden of Disease Attributable to Selected Major Risk Factors. Geneva: World Health Organization; 2004.
Chobanian AV. Shattuck Lecture. The hypertension paradox - more uncontrolled disease despite improved therapy. N Engl J Med. 2009;361:878–887.
Wolf-Maier K, Cooper RS, Kramer H, et al. Hypertension treatment and control in five European countries, Canada, and the United States. Hypertension. 2004;43:10–17.
Thoenes M, Neuberger HR, Volpe M, Khan BV, Kirch W, Böhm M. Antihypertensive drug therapy and blood pressure control in men and women: an international perspective. J Hum Hypertens. 2010;24:536–544.
Antikainen RL, Moltchanov VA, Chukwuma C Sr, et al. WHO MONICA Project. Trends in the prevalence, awareness, treatment and control of hypertension: the WHO MONICA roject. Eur J Cardiovasc Prev Rehabil. 2006;13:13–29.
Falaschetti E, Chaudhury M, Mindell J, Poulter N. Continued improvement in hypertension management in England: results from the Health Survey for England 2006. Hypertension. 2009;53:480–486.
Mancia G, De Backer G, Dominiczak A, et al. 2007 Guidelines for the management of arterial hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J. 2007;28:1462–1536.
Law MR, Morris JK, Wald NJ. Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies. BMJ 2009;338:(doi: 10.1136/bmj.b1665).
De Bacquer D, De Backer G. The prevalence of concomitant hypertension and hypercholesterolaemia in the general population. Int J Hypertens. 2006;110:217–223.
Heran BS, Galm BP, Wright JM. Blood pressure lowering efficacy of alpha blockers for primary hypertension. Cochrane Database Syst Rev. 2009;4:CD004643.
Zusman RM. The role of alpha 1-blockers in combination therapy for hypertension. Int J Clin Pract. 2000;54:36–40.
van Zwieten PA, Blauw GJ, van Brummelen P. Pharmacological profile of antihypertensive drugs with serotonin receptor and alpha-adrenoceptor activity. Drugs. 1990;40(suppl. 4):1–8.
Dooley M, Goa KL. Urapidil. A reappraisal of its use in the management of hypertension. Drugs. 1998;56:929–955.
Zanchetti A. Addition of urapidil or metoprolol to the treatment of hypertensive non-responders to nifedipine monotherapy: efficacy and metabolic effects. Italian Urapidil Study Group. Blood Press Suppl. 1995;3:38–46.
Mizuno K, Fukuchi S. Antihypertensive effectiveness of urapidil alone and in combination with nifedipine in mild to moderate essential hypertension. Curr Ther Res. 1991;50:274–281.
Fariello R, Dal Palu C, Pessina A, et al. Antihypertensive efficacy of urapidil versus hydrochlorothiazide alone in patients with mild to moderate essential hypertension and of their combination in nonresponders to monotherapy. Drugs. 1990;40(suppl. 4):60–62.
Kaneko Y. Double-blind comparison of urapidil and prazosin in the treatment of patients with essential hypertension. Drugs. 1988;35(suppl. 6):156–163.
Takeda T, Kaneko Y, Shionoiri H, et al. Urapidil in patients with severe hypertension and in long-term treatment. J Hypertens Suppl. 1988;6:S37–42.
Mancia G, Grassi G, Zanchetti A. New-onset diabetes and antihypertensive drugs. J Hypertens. 2006;24:3–10.
Elliott WJ, Meyer PM. Incident diabetes in clinical trials of antihypertensive drugs: a network metaanalysis. Lancet. 2007;369:201–207.
Fariello R, Boni E, Corda L, Zaninelli A, Noseda A, Spinazzi A. Influence of a new multifactorial antihypertensive on blood pressure and metabolic profile in essential hypertension associated with non-insulin-dependent diabetes mellitus. Eur Heart J. 1992;13(suppl. A):65–69.
Oren S, Turkot S, Paran E, Flandra O, Slezak L, Hof B. Efficacy and tolerability of slow release urapidil (ebrantil) in hypertensive patients with non-insulin dependent diabetes mellitus (NIDDM). J Hum Hypertens. 1996;10:123–127.
Goto Y. Effects of sustained-release urapidil on essential hypertension and hyperlipidaemia: a multicenter clinical trial. Curr Ther Res. 1992;51:870–876.
Ferrara LA, Leonetti G, Fogari R, Mazzola C, Mancini M, Zanchetti A. Urapidil in hypercholesterolemic hypertensive patients. Blood Press Suppl. 1994;4:39–44.
Pattenier JW, von Heusinger FC. Effect of urapidil treatment on lipid metabolism in patients with hypertension. Royal Soc Med Int Congr Symp. 1992:196:61–67.
Gerber A, Weidmann P, Marone C, Uehlinger D, Riesen W. Cardiovascular and metabolic profile during intervention with urapidil in humans. Hypertension. 1985;7:963–971.
Held K, Cremer P, Hundertmark E, Seidel D. Effects of long-term antihypertensive therapy with Urapidil (EbrantilR) on lipometabolism. Hochdruck. 1985;5:2.
Liebau H, Wurst W, Harder I, Solleder P. Metabolically neutral therapy of hypertension. An open, multicenter, prospective long-term study of the tolerance, safety and effectiveness of urapidil [in German]. Fortschr Med. 1988;106:651–654.
Haenni A, Lithell H. Urapidil treatment decreases plasma fibrinogen concentration in essential hypertension. Metabolism. 1996;45:1221–1229.
Ernst E, Resch KL. Fibrinogen as a cardiovascular risk factor: a meta-analysis and review of the literature. Ann Intern Med. 1993;118:956–963.
Danesh J, Lewington S, Thompson SG, et al. Plasma fibrinogen level and the risk of major cardiovascular diseases and nonvascular mortality: an individual participant meta-analysis. JAMA. 2005;294:1799–1809.
Sebekova K, Fedelesova V, Blazicek P, Dzurik R. Acute effect of urapidil on peripheral serotonin metabolism. Cor Vasa. 1990;32:274–281.
Smith CC, Betteridge DJ, Prichard BN. Platelet in vitro responses to urapidil and prazosin. Drugs. 1990;40(suppl. 4):48–51.
Storck J, Ochs JG, Kirsten R. Effects of urapidil on 5-hydroxytryptamine induced platelet aggregation and on 14C-5-hydroxytryptamine uptake in platelets. Int J Clin Pharmacol Ther Toxicol. 1990;28:303–308.
Kawabe K, Tsuchida S, Shimazaki J, Morita T, Yasuda K, Kageyama S. Effect on urapidil on benign prostatic hypertrophy: a multicenter, double-blind study. Urol Int. 1993;50:27–32.
Yasuda K, Yamanishi T, Kawabe K, Ohshima H, Morita T. The effect of urapidil on neurogenic bladder: a placebo controlled double-blind study. J Urol. 1996;156:1125–1130.
Yamanishi T, Yasuda K, Homma Y, Kawabe K, Morita T. A multicenter placebo-controlled, double-blind trial of urapidil, an alpha-blocker, on neurogenic bladder dysfunction. Eur Urol. 1999;35:45–51.
Yamanishi T, Yasuda K, Kamai T, et al. Combination of a cholinergic drug and an alpha-blocker is more effective than monotherapy for the treatment of voiding difficulty in patients with underactive detrusor. Int J Urol. 2004;11:88–96.
Ikeda Y, Takagi N, Takeda K. Clinical evaluation of urapidil in hypertensive patients with renal failure. Shinyaku to Rinsho. 1992;41:622–631.
de Leeuw PW, van Es PN, de Bruyn HA, Birkenhäger WH. Renal haemodynamic and neurohumoral responses to urapidil in hypertensive man. Drugs. 1988;35(suppl. 6):74–77.
Lavrijssen AT, Kroon AA, Fuss-Lejeune M, Schiffers PM, de Leeuw PW. Renal haemodynamics and sodium excretory capacity during urapidil treatment in patients with essential hypertension. J Hypertens. 2000;18:963–969.
Liebau H, Wurst W, Harder I, Solleder P. Metabolically neutral therapy of hypertension. An open, multicenter, prospective long-term study of the tolerance, safety and effectiveness of urapidil. Fortschr Med. 1988;106:651–654.
Liebau H, Solleder P, Harder I, Wurst W. Long-term antihypertensive therapy with urapidil. A 3-year open, multicenter trial of tolerance, safety and effectiveness. Fortschr Med. 1990;108:325–328.
Haerlin R. Treatment of primary and secondary hypertension. Long-term use of urapidil (Ebrantil®). Clinical Trials J. 1985;22:215–225.
Cherney D, Straus S. Management of patients with hypertensive urgencies and emergencies: a systematic review of the literature. J Gen Intern Med. 2002;17:937–945.
Perez MI, Musini VM. Pharmacological interventions for hypertensive emergencies. Cochrane Database Syst Rev. 2008;1:CD003653.
Agence Française de Sécurité Sanitaire Des Produits de Santé (AFSSAPS). Poussees hypertensives de l’adulte: elevation tensionnelle sans souffrance viscerale immediate et urgences hypertensives [in French]. Agence Française de Sécurité Sanitaire Des Produits de Santé, Saint Denis, France, May 2002. Available at www.afssaps.fr/var/afssaps_site/storage/original/application/460262f69aa6b448962c08cba7d8be4f.pdf. Accessed May 24, 2010.
Slany J, Magometschnigg D, Mayer G, et al. Klassifikation, Diagnostik und Therapie der Hypertonie 2007 - Empfehlungen der Österreichischen Gesellschaft für Hypertensiologie [in German]. J Hypertonie. 2007;11:7–11.
Zähringer J, Klepzig M, Greif J, Ludwig B, Strauer B. Therapy of the hypertensive crisis with urapidil. Various effects on patients with or without coronary disease. Fortschr Med. 1984;102:624–628.
Błaszyk K, Grajek S, Skorupski W, et al. Evaluation of the antihypertensive efficacy of urapidil in the treatment of hypertension emergencies [in Polish]. Pol Arch Med Wewn. 1995;94:512–517.
Alijotas-Reig J, Bove-Farre I, de Cabo-Frances F, Angles-Coll R. Effectiveness and safety of prehospital urapidil for hypertensive emergencies. Am J Emerg Med. 2001;19:130–133.
Jelakovic B, Grba-Bujevic M, Bosan-Kilibarda I, et al. Hypertensive crisis. Efficacy and safe of urapidil based protocol in out-of-hospital settings. J Hypertens. 2009;27(suppl. 4):S122, P11.305.
Hirschl MM, Seidler D, Zeiner A, et al. Intravenous urapidil versus sublingual nifedipine in the treatment of hypertensive urgencies. Am J Emerg Med. 1993;11:653–656.
Hirschl MM, Seidler D, Müllner M, et al. Efficacy of different antihypertensive drugs in the emergency department. J Hum Hypertens. 1996;10(suppl. 3):S143–146.
Hirschl MM, Binder M, Bur A, et al. Safety and efficacy of urapidil and sodium nitroprusside in the treatment of hypertensive emergencies. Intensive Care Med. 1997;23:885–888.
Woisetschläger C, Bur A, Vlcek M, Derhaschnig U, Laggner AN, Hirschl MM. Comparison of intravenous urapidil and oral captopril in patients with hypertensive urgencies. J Hum Hypertens. 2006;20:707–709.
Späh F, Grosser KD, Thieme G. Acute haemodynamic effects of urapidil and nifedipine in hypertensive urgencies and emergencies. Drugs. 1990;40(suppl. 4):58–59.
Wacker J, Werner P, Walter-Sack I, Bastert G. Treatment of hypertension in patients with preeclampsia: a prospective parallel-group study comparing dihydralazine with urapidil. Nephrol Dial Transplant. 1998;13:318–325.
Wacker JR, Wagner BK, Briese V, et al. Antihypertensive therapy in patients with preeclampsia: A prospective randomised multicentre study comparing dihydralazine with urapidil. Eur J Obstet Gynecol Reprod Biol. 2006;127:160–165.
Schulz M, Wacker J, Bastert G. Effect of Urapidil in antihypertensive therapy of preeclampsia on newborns [in German]. Zentralbl Gynakol. 2001;123:529–533.
Deutsche Hochdruckliga e.V. DHLR - Deutsche Hypertonie Gesellschaft. Leitlinien zur behandlung der arteriellen hypertonie. Heidelberg, Germany, 2008. Available at: www.hochdruckliga.de. Accessed: May 24, 2010.
Olmos M, Vidarte MA, Ballester JA, Lasuen J, Escobar A. Efficacy of a single dose of urapidil for preventing arterial hypertension during the pre-bypass period in coronary surgery. Rev Esp Anestesiol Reanim. 2000;47:337–342.
Gob E, Barankay A, Richter JA. Control of hypertension during cardiopulmonary bypass with urapidil and phentolamine. Arzneimittelforschung. 1981;31:1479–1481.
Hess W. Urapidil versus clonidine. Acute haemodynamic effects during control of intraoperative hypertensive episodes. Drugs. 1990;40(suppl. 4):77–79.
Hess W, Schulte-Sasse U, Tarnow J, Veit S. Comparison of phentolamine and urapidil in controlling acute intra-operative hypertension in patients subjected to coronary artery bypass surgery. Eur J Anaesthesiol. 1985;2:21–27.
Petry A, Wulf H, Baumgartel M. The influence of ketanserin or urapidil on haemodynamics, stress response and kidney function during operations for myocardial revascularisation. Anaesthesia. 1995;50:312–316.
van der Stroom JG, Van Wezel HB, Koolen JJ, Visser CA, Van Zwieten PA. Comparison of the effects of urapidil and nitroprusside on hemodynamics and myocardial function in hypertension following cardiac surgery. Blood Press Suppl. 1994;4:31–38.
van der Stroom JG, van Wezel HB, Langemeijer JJ, et al. A randomized multicenter double-blind comparison of urapidil and ketanserin in hypertensive patients after coronary artery surgery. J Cardiothorac Vasc Anesth. 1997;11:729–736.
van der Stroom JG, van Wezel HB, Vergroesen I, et al. Comparison of the effects of urapidil and sodium nitroprusside on haemodynamic state, myocardial metabolism and function in patients during coronary artery surgery. Br J Anaesth. 1996;76:645–651.
Mollhoff T, Van Aken H, Mulier JP, Muller E, Lauwers P. Effects of urapidil, ketanserin and sodium nitroprusside on venous admixture and arterial oxygenation following coronary artery bypass grafting. Br J Anaesth. 1990;64:493–497.
van Hemelrijck J, Waets P, Aken H van, Lacroix H, Nevelsteen A, Suy R. Blood pressure management during aortic surgery - Urapidil compared to isosorbide dinitrate. J Cardiothorac Vasc Anesth. 1993;7:273–278.
Zander J, Puchstein C, Aken H van, Lawin P. Urapidil as a supplement to neuroleptanalgesia during neuroanaesthesia. Br J Anaesth. 1984;56:1304–1305.
Puchstein C, Van Aken H, Zander J, Lawin P. The use of urapidil in the postoperative period. Anaesthesist. 1984;33:224–227.
Gosse P, Tauzin-Fin P, Sesay MB, Sautereau A, Ballanger P. Preparation for surgery of phaeochromocytoma by blockade of alpha-adrenergic receptors with urapidil: what dose? J Hum Hypertens. 2009;23:605–609.
Spah F, Walsemann SO. Potential beneficial effects of urapidil in primary and secondary prevention of stroke. Blood Press Suppl. 1995;3:62–67.
Wusten R, Hemelrijck J, Mattheussen M, Lauvers T, Anger C, van Aken H. Der einfluss von nifidepin und urapidil auf die autoregulation der zerebralen durchbtuling in gegenwart einer intrakraniellen raumforderung [in German]. Anasth Intensivther Notfallmed. 1990;25:140–145.
Prehn JH, Backhauss C, Karkoutly C, et al. Neuroprotective properties of 5-HT1A receptor agonists in rodent models of focal and global cerebral ischemia. Eur J Pharmacol. 1991;203:213–222.
European Stroke Initiative Executive Committee. European Stroke Initiative Recommendations for Stroke Management-update 2003. Cerebrovasc Dis. 2003;16:311–337.
Anderson CS, Huang Y, Wang JG, et al. Intensive blood pressure reduction in acute cerebral haemorrhage trial (INTERACT): a randomised pilot trial. Lancet Neurol. 2008;7:391–399.
ALLHAT Collaborative Research Group. Major cardiovascular events in hypertensive patients randomized to doxazosin vs. chlorthalidone: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). JAMA. 2000;283:1967–1975.
ALLHAT officers and coordinators for the ALLHAT Collaborative Research Group. Diuretics versus alpha blockers as first-step antihypertensive therapy. Hypertension. 2003;42:239–246.
Chobanian AV, Bakris GL, Black HR, et al; Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. National Heart, Lung, and Blood Institute; National High Blood Pressure Education Program Coordinating Committee. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension. 2003;42:1206–1252.
Chapman N, Chang CL, Dahlöf B, et al. Effect of doxazosin gastrointestinal therapeutic system as third-line antihypertensive therapy on blood pressure and lipids in the Anglo-Scandinavian Cardiac Outcomes Trial. Circulation. 2008;118:42–48.
Spoladore R, Roccaforte R, Fragasso G, et al. Safety and efficacy of doxazosin as “add-on” antihypertensive therapy in mild to moderate heart failure patients. Acta Cardiol. 2009;64:485–491.
Belz GG, Matthews JH, Graf D, et al. Dynamic responses to intravenous urapidil and dihydralazine in normal subjects. Clin Pharmacol Ther. 1985;37:48–54.
Kobrin I, Amodeo C, Ventura HO, Messerli FH, Frohlich ED. Immediate hemodynamic effects of urapidil in patients with essential hypertension. Am J Cardiol. 1985:722–725.
Stoschitzky K, Stoschitzky G, Wonisch M, Brussee H. Differential effects of urapidil and doxazosin on heart rate. Eur J Clin Pharmacol. 2007;63:259–262.
Hansson L, Petitet A. Review of studies with urapidil in elderly hypertensives. Blood Press Suppl. 1995;3:21–25.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Buch, J. Urapidil, a dual-acting antihypertensive agent: Current usage considerations. Adv Therapy 27, 426–443 (2010). https://doi.org/10.1007/s12325-010-0039-0
Received:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12325-010-0039-0